• GC Biopharma's third-quarter 2026 operating profit rose 68.5% year over year to KRW 49.2 billion.
• Revenue fell 14.3% year over year to KRW 522.1 billion.
• Net profit surged 1,051.9% year over year to KRW 208.5 billion.
• Nine-month operating profit declined 2.8% to KRW 62.7 billion.
• Revenue for the nine months dropped 7.7% to KRW 1.38 trillion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GC Biopharma Corp. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800193), on November 02, 2026, and is solely responsible for the information contained therein.